Author: Contec Healthcare
Tags:Compounding Pharmacy, Webinar

Using Bugs as Drugs: Compounding Viral Vectors in Cell & Gene Therapy for Hospital Pharmacies

This Contec Healthcare session introduces cell and gene therapy (CGT) and its intersection with compounding pharmacy practice. 
00:0300:05

Webinar Description

 

Learn more about compounding cell and gene therapies, risk assessments, and how to implement appropriate measures to avoid cross-contamination and occupational exposure in hospital pharmacies.

 

Key Takeaways

  • Cell and gene therapy is a rapidly emerging field in healthcare.
  • Viral vectors (“bugs”) are used as delivery systems for treatment.
  • The field is new, with significant ongoing development and learning.
  • Hospital pharmacies play a growing role in handling these therapies.
  • These products require strict handling, storage, and preparation controls.
  • The future of pharmacy will increasingly include advanced biologic therapies.

Webinar Materials

Webinar Section Summaries

Overview of Cell and Gene Therapy

 

Cell and gene therapy involves:

 

  • Modifying or using living cells
  • Delivering genetic material to treat disease

 

These therapies represent a shift from traditional pharmaceuticals toward biologically engineered treatments.

 

Evolution and Novelty of the Field

The field is described as very new, with the first FDA-approved product emerging in 2017.

 

Key implications:

 

  • Rapid innovation
  • Ongoing learning across the industry
  • Limited historical precedent

 

Even experts are still developing best practices as the field evolves.

 

Types of Cell Therapies (CAR-T, NK Cells)

 

The webinar introduces major cell therapy types, including:

 

  • CAR-T cell therapy
  • NK (Natural Killer) cell therapy

 

These therapies involve engineering immune cells to target and treat diseases such as cancer.

 

Viral Vectors as Therapeutic Tools

 

“Using bugs as drugs” refers to viral vectors, which are engineered viruses used to deliver genetic material into cells.

 

Key points:

 

  • Viruses are modified to be safe and therapeutic
  • They act as delivery systems for gene therapy
  • They are central to many CGT products

 

Manufacturing Process: From Lab to Patient

 

The process includes:

 

  • Cell or vector development in specialized facilities
  • Controlled manufacturing processes
  • Distribution to healthcare settings

 

The complexity of manufacturing requires strict controls and coordination across multiple stages.

 

Role of Hospital Pharmacies in Cell & Gene Therapy

 

Hospital pharmacies may be involved in:

 

  • Receiving CGT products
  • Preparing them for administration
  • Managing storage and handling

 

This expands the traditional role of pharmacy into highly specialized biologic therapies.

 

Handling, Preparation, and Compounding Considerations

 

Handling CGT products involves:

 

  • Strict environmental controls
  • Specialized storage conditions
  • Careful preparation techniques

 

While not always “compounding” in the traditional sense, these activities require similar levels of precision and control.

 

Challenges and Future Outlook

 

Challenges include:

 

  • Rapidly evolving standards
  • Limited regulatory clarity
  • High complexity of therapies

 

However, the field is expected to grow significantly, making it increasingly relevant to hospital pharmacy practice.

 

Behind the Scenes